Glyscend Therapeutics

Glyscend Therapeutics

  • Founded: 2014
  • Location: Baltimore, MD
  • Employee range: 11 - 50
  • Funding: 10-100M

job board

Short description:

Non-Invasive Bariatric Bypass Technology

Drug notes:

Contact us to add description:

Long description:

Glyscend is developing a novel approach to treat type 2 diabetes and obesity. Bariatric surgery is an invasive form of surgery that makes changes to the digestive system to help patients lose weight. Glyscend is working to mimic the effect of bariatric surgery with an oral pill such that invasive and expensive surgeries can be avoided. Glyscend’s drugs are based on their polymer therapeutic platform that can form a reversible coating in the gastrointestinal (GI) tract, providing a dynamic barrier to prevent interaction between the food and the mucosal surface of the intestine. Their lead pharmacologic polymer product, GLY-200, has advanced to the clinic with a Phase 2 study ongoing in type 2 diabetic patients.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy